Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR-MS: oral cladribine versus rituximab in relapsing multiple sclerosis
2019-001505-24Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple sclerosis (MS) comparing Rituximab with Oral cladribine (2 arms). Primary endpoint: Number of new or enlarging cerebral MRI T2 lesions per patient from week 12 to week 96. Started May 2019; status: completed.
02
Drugs
rituximabcladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-001505-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001505-24.